AMRN
Drug Manufacturers - General · Healthcare
CFO
Equibles does not estimate personal net worth.
Get an email with a short summary when Amarin Corp Plcuk publishes a filing, an earnings call transcript or a press release.
Get AMRN alertsPeter L. Fishman is recorded as CFO at Amarin Corp Plcuk (AMRN). The newest filing on record that lists Peter L. Fishman as CFO at Amarin Corp Plcuk (AMRN) is dated April 10, 2026. The proxy statement of Amarin Corp Plcuk reports total compensation of $1,036,970 for Peter L. Fishman in fiscal 2025, including a base salary of $400,000. Disclosed compensation is on record for 2 fiscal years. Peter L. Fishman has spoken on 8 earnings calls across 1 company, most recently for Amarin Corp Plcuk on October 28, 2026. Amarin Corp Plcuk is classified in the Drug Manufacturers - General industry within the Healthcare sector. Other leadership on record at Amarin Corp Plcuk includes Aaron D. Berg (CEO), Patrick Holt (CEO and Board Member), Odysseas D. Kostas (Chairman) and 7 others.
“We reported our first profitable quarter in two years, reflecting the benefits of our completed restructuring, as well as our company-managed U.S. and fully partnered international commercial model.”
“As Aaron mentioned, the benefits of our dual sales model and now-completed restructuring plan are becoming increasingly clear with execution against three key priorities.”
“Our results for the first quarter of 2026 reflected the continuing traption of our new business model and our global restructuring plan. Given the adoption of our new agreement with Recordati, I will in some cases also compare consecutive quarterly results, Q4 2025 to Q1 2026, to highlight recent progress.”
“At the end of the third quarter of 2025, our business continues to demonstrate financial discipline with operating margin and cash flow trends positioned for steady improvement.”
“Q2 2025 total net revenue was $72.7 million, an increase of $5.3 million or 8% versus the prior year period, primarily reflecting the impact of the Recordati upfront payment.”
Start not stated–present
Last confirmed April 10, 2026
AMRN
Drug Manufacturers - General · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Amarin Corp Plcuk (AMRN) | Senior Vice President, Chief Financial Officer | $400,000 | $1,036,970 |
| 2024 | Amarin Corp Plcuk (AMRN) | Senior Vice President, Chief Financial Officer | $310,170 | $606,000 |